Sector News

Cue the ‘revolving door’ criticism: Former FDA commissioner Gottlieb joins Pfizer’s board

July 1, 2019
Life sciences

When former FDA commissioner Scott Gottlieb, M.D., resigned back in March, he said he wanted to spend more time with his family.

Since then, Gottlieb has nabbed a partnership at a VC firm and a think tank fellowship. And now, less than three months since his last day regulating pharma, Gottlieb has joined Pfizer, one of the biggest companies in the business.

Gottlieb snagged a spot on Pfizer’s board of directors, the drug giant said Thursday. He’ll also serve on the board’s regulatory and compliance committee and its science and technology committee.

The announcement comes 85 days after Gottlieb left the FDA on April 5 to spend more time with his family. In his resignation letter to colleagues, Gottlieb wrote that “there’s nothing that could pull me away from this role other than the challenge of being apart from my family for these past two years and missing my wife and two young children.”

Since leaving the FDA, Gottlieb joined New Enterprise Associates as a special partner. He’s also a resident fellow at the American Enterprise Institute, according to Pfizer.

While the new roles surely aren’t as demanding as FDA commissioner, Gottlieb’s quick jump back to industry is sure to raise eyebrows. He was arguably among the most popular Trump appointments as agency chief, but his quick leap back to industry conflicts with President Donald Trump’s campaign pledge to “drain the swamp” and fight corporate influence in Washington.

Pfizer Executive Chairman Ian Read said Gottlieb’s “expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a board representing a balance of experience, competencies and perspectives.”

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”